Demócrata reports Lilly's oral GLP-1 met cardiovascular safety and lowered blood sugar and weight in type 2 diabetes. Few details beyond the headline.
Recap by typeshit. Full story at Demócrata.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Drugs.com
An evergreen explainer on diagnosis and treatment options, noting Wegovy and Zepbound can bring about 15% to 21% weight loss with lifestyle changes.
Trefis says investors are watching whether MariTide's vomiting rate lands in the mid-20s or lower. Amgen also dropped an early obesity drug, AMG 513.
Loading…